Millie
your market intelligence analyst
Search Results
108 results
Your search is now limited to «Non-Hodgkin Lymphoma» expert search.
Onclive 07/11/2019 14:32
Jing-Zhou Hou, MD, PhD, highlights the research being conducted in the realm of lymphoma, including positive and negative trials that have read out in the space, and provides insight into novel approaches under investigation.
More from Onclive:
BioNewsFeeds 07/11/2019 13:02
The safety and effectiveness of the investigational therapy, either alone or in combination with other therapies, is being evaluated in the ongoing UNITY-NHL trial in patients with relapsed or refractory non-Hodgkin’s lymphoma.
More from BioNewsFeeds:
PubMed News (NIH) 07/10/2019
Contributors : Jason P Wong ; Timothy J Stuhlmiller ; Louise C Giffin ; Carolina Lin ; Steven I Park ; Gary L Johnson ; Blossom Damania Series Type : Expression profiling by high throughput sequencing Organism : Homo sapiens. Non-Hodgkin’s lymphomas (NHL) make up the majority of lymphoma diagnoses and represent a very diverse set of malignancies.
More from PubMed News (NIH):
GlobeNewswire 07/09/2019 08:30
The hematologic cancers being studied in the trial include multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-Cell lymphoma (DLBCL.
More from GlobeNewswire:
ClinicalTrials.gov 07/09/2019 07:26
Conditions : Relapsed Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma Intervention : Combination Product: CD19 CART Sponsors : Chinese PLA General Hospital; Shenzhen University; Shenzhen University General Hospital Recruiting.
More from ClinicalTrials.gov:
However, survivors of NHL treated with LMB and non-LMB regimens did not differ with regard to risk of having any chronic health conditions, impaired health status, neurocognitive deficits, or poorer socioeconomic outcomes.
More from American Society of Clinical Oncolgy (ASCO):
PR Newswire 06/22/2019 02:30
An ongoing, global, Phase 2 study is evaluating the efficacy, safety, and tolerability of ME-401 as a single agent in patients with follicular lymphoma after failure of at least two prior systemic therapies including chemotherapy and an anti-CD20 antibody.
More from PR Newswire:
Business Wire 06/21/2019 07:00
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced an oral presentation highlighting supportive Phase 1 clinical data for duvelisib (COPIKTRA™) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) at the 2019 International Conference on Malignant Lymphoma (ICML) being he.
More from Business Wire:
Benzinga 06/21/2019 01:00
The findings support the continued evaluation of ADCT-402 in ongoing clinical trials in patients with R/R DLBCL and other types of non-Hodgkin lymphoma.
More from Benzinga:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications